Trial reportDrug and alcohol dependence2010
A double-blind, placebo-controlled, randomized clinical trial of oral selegiline hydrochloride for smoking cessation in nicotine-dependent cigarette smokers.
Trial report in Drug and alcohol dependence, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 3 syntheses or guidelines pooled it, 42 citations in OpenAlex.
- Antidepressants for smoking cessation.The Cochrane database of systematic reviews · 2020Pooled it
- Antidepressants for smoking cessation.The Cochrane database of systematic reviews · 2014Pooled it
- Smoking cessation interventions for smokers with current or past depression.The Cochrane database of systematic reviews · 2013Pooled it
- Response to Transdermal Selegiline Smoking Cessation Therapy and Markers in the 15q24 Chromosomal Region.Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco · 2015Trial
- A selective reversible monoamine oxidase B inhibitor in smoking cessation: effects on its own and in association with transdermal nicotine patch.Psychopharmacology · 2012Trial
- Selegiline transdermal system (STS) as an aid for smoking cessation.Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco · 2012Trial
- Differences in smoking expectancies in smokers with and without a history of major depression.Addictive behaviors · 2011Trial
- Changes in smoking expectancies in abstinent, reducing, and non-abstinent participants during a pharmacological trial for smoking cessation.Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco · 2010Trial
- Review
- Antidepressants for smoking cessation.The Cochrane database of systematic reviews · 2023Review
- Monoamine oxidase inhibition in cigarette smokers: From preclinical studies to tobacco product regulation.Frontiers in neuroscience · 2022Review
- Protective effect of selegiline on cigarette smoke-induced oxidative stress and inflammation in rat lungsAnnals of translational medicine · 2020Article
- Why are Antidepressant Drugs Effective Smoking Cessation Aids?Current neuropharmacology · 2018Review
- Pharmacokinetic Drug Interactions with Tobacco, Cannabinoids and Smoking Cessation Products.Clinical pharmacokinetics · 2016Review
- Targeting the noradrenergic system for gender-sensitive medication development for tobacco dependence.Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco · 2015Review
- Pharmacotherapy for smoking cessation: pharmacological principles and clinical practice.British journal of clinical pharmacology · 2014Review
- Review
- Treatment of nicotine addiction: present therapeutic options and pipeline developments.Trends in pharmacological sciences · 2011Review
- Therapeutic advances in the treatment of nicotine addiction: present and future.Therapeutic advances in chronic disease · 2010Article
- Current pharmacologic treatments for smoking cessation and new agents undergoing clinical trials.Therapeutic advances in respiratory diseaseReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 2 countries.
Funding
Abstract
aimThe primary aim of this study was to determine the safety and efficacy of the monoamine oxidase-B (MAO-B) inhibitor selegiline hydrochloride (SEL, l-Deprenyl; Eldepryl) as an aid for smoking cessation in cigarette smokers.
methodsOne hundred and one nicotine-dependent adult cigarette smokers without current psychiatric or substance use disorders participated in this 8-week randomized, double-blind, placebo-controlled trial. Participants received either SEL (5mg bid, n=51) or placebo (PLO, n=50), in combination with brief (<10 min) manualized smoking cessation counseling. The main smoking outcome measures were 7-day point prevalence abstinence at end of trial (EOT), 4-week continuous smoking abstinence at end of trial (CA), and 7-day point prevalence abstinence at 6-month follow-up (6MFU). Abstinence was determined by an absence of self-reported cigarette smoking and biochemically verified by expired breath carbon monoxide and plasma cotinine levels.
resultsRates of smoking abstinence did not differ by medication group (EOT: SEL=16%, PLO=20%, p=0.57; CA: SEL=14%, PLO=18%, p=0.56; 6MFU: SEL=12%, PLO=16%, p=0.54). Adverse events were modest and comparable between medication groups. Participants receiving SEL were more likely than those receiving PLO to report dry mouth (25.5% versus 8.2%, p<0.05).
conclusionsOur results suggest that SEL was safe and well-tolerated by adult cigarette smokers, but did not improve smoking abstinence rates compared to PLO.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.